在近期发布的医学研究中,巴塞罗那IDIBAPS研究所的F. Schettini博士及其团队在ESMO Open杂志上发表了一项开创性研究[1],深入探讨了新辅助化疗(NACT)和新辅助内分泌治疗(NET)对激素受体阳性(HR+)/HER2低表达(HER2-low)与 HR+/HER2-0乳...
然后点右上角“…”菜单,选择“设为星标” HER2作为一种高度敏感的治疗靶点,经过既往长期的探索,已然成为治疗高度侵袭性HER2阳性乳腺癌(HER2+ BC)的重大突破。近年来,HER2低表达(HER2-low)也成为乳腺癌诊疗的热点话题,然而抗HER2的经典靶向药物,...
然后点右上角“…”菜单,选择“设为星标” HER2作为一种高度敏感的治疗靶点,经过既往长期的探索,已然成为治疗高度侵袭性HER2阳性乳腺癌(HER2+ BC)的重大突破。近年来,HER2低表达(HER2-low)也成为乳腺癌诊疗的热点话题,然而抗HER2的经典靶向药物,如曲妥珠单抗等,往往对HER2低表达患者无效,传统疗法仍旧是HER2低表达患...
25.6%(11/43)的基线 HER2-0 患者在 NAC 后变为 HER2-low,并且这种分类变化在 HR 阳性肿瘤中更为显著。本研究结果支持在NAC后有残留病灶的患者中重新检测HER2表达,这有助于识别可能获益于针对HER2-low BC的HER2药物的患者。需要进行更大队列研究,以验证本单机构经验,并进一步探索 NAC 后 HER2 分类变化的预后价...
HER2阴性及HER2-low BC目前的治疗模式 目前IHC 0、1+或2+/ISH阴性转移性乳腺癌(mBC)的治疗模式因HR状态而异(图2)。在HR+患者中,治疗通常包括以下药物序列[2,8-9]:一线(1L):内分泌治疗(ET)+ CDK4/6抑制剂(CDK4/6I);二线(2L):ET再挑战(单药)、ET+CDK4/6i(如果1L未使用)、ET+依维莫司或化疗...
过去的临床研究结果显示,曲妥珠单抗未能改善 HER2-low BC 患者的预后,因此在这种情况下抗 HER2 药物用于这类患者治疗的的策略逐渐被搁置。但非常幸运的是,鉴于新型和更有效的抗 HER2 药物在 HER2-low mBC 中看到了具有临床希望的疗效结果,这种治疗模式重新跃入众人视野。
innovative treatmentaccessRecent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed 'HER2-low' has been identified in tumors ...
[4]Giuseppe Viale,et al.Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.J Clin Oncol 40, 2022 (suppl 16; abstr 1087) [5]Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2...
The pCR rate was significantly lower in HER2-low BC compared to HER2-0 BC within the HR-positive group (4% versus 5%; p=0.022). However, the absolute difference was limited, so the clinical relevance is questionable. In HR-negative cases, the difference in pCR was not significant (32% ...
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be